# A Study to Evaluate the Safety and Tolerability of EP0089

> **NCT07030478** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Ellipses Pharma** · enrollment: 190 (estimated)

## Conditions studied

- Solid Cancers
- Solid Tumours

## Interventions

- **DRUG:** EP0089-101

## Key facts

- **NCT ID:** NCT07030478
- **Lead sponsor:** Ellipses Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2028-03
- **Final completion:** 2029-06
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030478, "A Study to Evaluate the Safety and Tolerability of EP0089". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07030478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*